SCHEMBL2835372

SCHEMBL2835372

COc1cc(C)c(S(=O)(=O)N2c3ccccc3C[C@H]2COc2ccnc(N3CCC(CCN4CCCCC4)CC3)n2)c(C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.35
CHRM4 P08173 1/20 0.34
DRD2 P14416 3/20 0.33
DRD3 P35462 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KMT2A Q03164 1/20 0.33
AVPR1A P37288 4/20 0.32
AVPR1B P47901 4/20 0.32
OXTR P30559 2/20 0.32
HTR2A P28223 2/20 0.32
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
BACE1 P56817 1/20 0.31
TSHR P16473 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
HTR7 P34969 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836242 0.99 HTR1A (0.36) HTR1ACHRM4DRD2DRD3CA12
SCHEMBL2360574 0.88 CA12 (0.38) HTR1ADRD2DRD3CA12CA1
SCHEMBL12150081 0.87 BDKRB1 (0.39) HTR1ACHRM4DRD2DRD3CA12
SCHEMBL2832998 0.86 HTR1A (0.40) HTR1ASMN1; SMN2
SCHEMBL2834634 0.85 HTR1A (0.40) HTR1ACA12CA1CA2CA9
SCHEMBL2836552 0.85 HTR7 (0.38) HTR1ACHRM4DRD2DRD3HTR2A
SCHEMBL2834109 0.85 HTR7 (0.40) HTR1ACHRM4DRD2DRD3HTR2A
SCHEMBL2836529 0.84 CA12 (0.38) CA12CA1CA2CA9KMT2A
SCHEMBL2839870 0.84 HTR7 (0.38) HTR1ACHRM4DRD2DRD3HTR2A
SCHEMBL2835296 0.84 HTR7 (0.40) HTR1ACHRM4DRD2DRD3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS HTR1A 199/4885CHRM4 2247/4885DRD2 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.